Xenon filed a 2025 operating loss of $373.1 million, a 2025 net loss of $345.9 million and Q1 2026 cash of $545.9 million. The thesis depends on clinical execution, regulatory progress and how long the balance sheet can fund development.
Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.
